2024年11月11日,Hims & Hers Health Inc.盘中股价暴涨26.35%,引发市场关注。从相关新闻披露的信息来看,该公司股价大涨主要受两大利好因素影响。
一方面,Hims & Hers Health最新一季度财报出炉,业绩表现优异。公司实现营业收入4.02亿美元,净利润达7559万美元,每股获益0.35美元。这一亮眼的业绩数据有力证明了这家远程医疗公司的良好发展前景,增强了市场投资者的信心。
另一方面,Hims & Hers Health计划于2025年推出一款热门减肥药利拉鲁肽的仿制药。目前这种类型的药物供不应求,存在着巨大的市场需求缺口。公司有望凭借仿制药的优势迅速抢占市场,这为未来业绩增长注入了新的动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.